Effects of apramycin, a novel aminoglycoside antibiotic on bacterial protein synthesis.
1. The novel aminoglycoside antibiotic apramycin is shown to be a potent inhibitor of protein synthesis in bacteria both in vivo and in vitro. 2. In cell-free systems from Escherichia coli programmed with poly(U), apramycin induces translation errors, as assayed by incorporation of leucine, isoleucine and serine, although this effect occurs only to a limited extent. 3. Apramycin inhibits the translocation step of protein synthesis both in vivo, in protoplasts of Bacillus megaterium, and in vitro, in cell-free systems from E. coli. It is proposed that this is the primary inhibitory effect of the drug.
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001410:Bacillus megaterium / Q000378:metabolism; D001426:Bacterial Proteins / Q000096:biosynthesis*; D004926:Escherichia coli / Q000378:metabolism*; D006921:Hygromycin B / Q000494:pharmacology; D007930:Leucine / Q000378:metabolism; D009328:Nebramycin / Q000031:analogs & derivatives / Q000494:pharmacology*; D011072:Poly U / Q000378:metabolism; D014176:Protein Biosynthesis / Q000187:drug effects; D011523:Protoplasts / Q000378:metabolism; D011691:Puromycin / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D009328:Nebramycin; D011072:Poly U; C011666:apramycin; D006921:Hygromycin B; D011691:Puromycin; D007930:Leucine